Nasdaq listed Forbion European Acquisition Corp (FEAC), the Forbion SPAC, and enGene, a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, have entered into a business combination agreement that will result in the combined company being listed on Nasdaq. The company will be named enGene Holdings. Financing for the…
Home Healthcare Markets International Business The Netherlands: Forbion SPAC and enGene to merge and list on Nasdaq